Antiarrhythmic Activity of Taurepar during Ischemic and Reperfusion Damage to Myocardium
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605537321 | ||
| 003 | CHVBK | ||
| 005 | 20210128100856.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20151201xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s10517-015-3135-y |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s10517-015-3135-y | ||
| 245 | 0 | 0 | |a Antiarrhythmic Activity of Taurepar during Ischemic and Reperfusion Damage to Myocardium |h [Elektronische Daten] |c [I. Krylova, V. Bul'on, E. Selina, N. Sapronov, P. Shabanov] |
| 520 | 3 | |a The antiarrhythmic effect of taurepar, an N-phenylalkyl derivative of taurine, was examined in experiments on rats subjected to acute myocardial ischemia/reperfusion leading to arrhythmia development. During acute ischemia, taurepar (25 mg/kg) completely prevented early postocclusion arrhythmias including extrasystoles, ventricular tachycardia, and ventricular fibrillation. During postischemic reperfusion, taurepar (25 mg/kg) did not prevent extrasystoles and ventricular tachycardia, but precluded the development of ventricular fibrillation and the death of animals. The antiarrhythmic potency of taurepar surpassed that of lidocaine during acute myocardial ischemia and that of propranolol during ischemia/reperfusion injury. The results suggest that taurepar is a promising antiarrhythmic drug with high antifibrillation activity. | |
| 540 | |a Springer Science+Business Media New York, 2015 | ||
| 690 | 7 | |a myocardium |2 nationallicence | |
| 690 | 7 | |a ischemia |2 nationallicence | |
| 690 | 7 | |a reperfusion |2 nationallicence | |
| 690 | 7 | |a arrhythmias |2 nationallicence | |
| 690 | 7 | |a taurepar |2 nationallicence | |
| 700 | 1 | |a Krylova |D I. |u Department of Neuropharmacology, Research Institute of Experimental Medicine, Russian Academy of Medical Sciences, St. Petersburg, Russia |4 aut | |
| 700 | 1 | |a Bul'on |D V. |u Department of Neuropharmacology, Research Institute of Experimental Medicine, Russian Academy of Medical Sciences, St. Petersburg, Russia |4 aut | |
| 700 | 1 | |a Selina |D E. |u Department of Neuropharmacology, Research Institute of Experimental Medicine, Russian Academy of Medical Sciences, St. Petersburg, Russia |4 aut | |
| 700 | 1 | |a Sapronov |D N. |u Department of Neuropharmacology, Research Institute of Experimental Medicine, Russian Academy of Medical Sciences, St. Petersburg, Russia |4 aut | |
| 700 | 1 | |a Shabanov |D P. |u Department of Neuropharmacology, Research Institute of Experimental Medicine, Russian Academy of Medical Sciences, St. Petersburg, Russia |4 aut | |
| 773 | 0 | |t Bulletin of Experimental Biology and Medicine |d Springer US; http://www.springer-ny.com |g 160/2(2015-12-01), 228-230 |x 0007-4888 |q 160:2<228 |1 2015 |2 160 |o 10517 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10517-015-3135-y |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a research-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s10517-015-3135-y |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Krylova |D I. |u Department of Neuropharmacology, Research Institute of Experimental Medicine, Russian Academy of Medical Sciences, St. Petersburg, Russia |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Bul'on |D V. |u Department of Neuropharmacology, Research Institute of Experimental Medicine, Russian Academy of Medical Sciences, St. Petersburg, Russia |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Selina |D E. |u Department of Neuropharmacology, Research Institute of Experimental Medicine, Russian Academy of Medical Sciences, St. Petersburg, Russia |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Sapronov |D N. |u Department of Neuropharmacology, Research Institute of Experimental Medicine, Russian Academy of Medical Sciences, St. Petersburg, Russia |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Shabanov |D P. |u Department of Neuropharmacology, Research Institute of Experimental Medicine, Russian Academy of Medical Sciences, St. Petersburg, Russia |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t Bulletin of Experimental Biology and Medicine |d Springer US; http://www.springer-ny.com |g 160/2(2015-12-01), 228-230 |x 0007-4888 |q 160:2<228 |1 2015 |2 160 |o 10517 | ||